http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Arrowhead receives China approval for rare disease drug REDEMPLO
-
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
-
Arrowhead Pharmaceuticals reports interim obesity drug trial results
-
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
-
Health Canada approves Arrowhead's REDEMPLO for rare triglyceride disorder
-
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
-
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals starts phase 1/2a trial for Alzheimer's drug
-
Arrowhead Pharmaceuticals begins Phase 1/2a trial of ARO-MAPT for Alzheimer's
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
-
Arrowhead gets FDA breakthrough therapy status for plozasiran drug
-
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
-
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
-
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
-
Arrowhead Pharmaceuticals receives $200 million from Sarepta milestone
-
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
-
FDA approves Arrowhead's REDEMPLO for rare triglyceride disorder
-
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
-
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
-
Arrowhead files application for dual-gene RNAi therapy trial
-
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
-
Arrowhead files lawsuit against Ionis over plozasiran patent dispute
-
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
-
Arrowhead Pharmaceuticals seeks approval for Alzheimer's drug trial
-
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
-
Arrowhead Pharmaceuticals partners with Novartis for $200 million deal
-
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
-
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
-
Arrowhead receives $100 million milestone from Sarepta in mixed payment
-
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
-
Sanofi acquires rights to plozasiran drug candidate in Greater China
-
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
-
Arrowhead receives $100 million milestone from Sarepta for ARO-DM1 study
-
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
-
Arrowhead starts phase 3 trial for rare cholesterol disorder drug
-
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
-
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
-
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
-
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
